OM
RLMD icon

Opaleye Management’s Relmada Therapeutics RLMD Stock Holding History

Opaleye Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.51M Hold
935,000
– – 0.86% 26
2025
Q4 		$4.52M Buy
+935,000
New +$3.13M 0.6% 32
2024
Q4 		– Sell
-480,000
Closed -$1.56M – 48
2024
Q3 		$1.56M Sell
480,000
-120,000
-20% -$389K 0.26% 37
2024
Q2 		$1.8M Sell
600,000
-159,000
-21% -$575K 0.41% 42
2024
Q1 		$3.53M Sell
759,000
-118,000
-13% -$569K 0.77% 33
2023
Q4 		$3.63M Buy
877,000
+847,000
+2,823% +$2.51M 0.97% 25
2023
Q3 		$90K Buy
+30,000
New +$89.1K 0.03% 40

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Opaleye Management's RLMD Position: Q1 2026 in Review

Opaleye Management held its Relmada Therapeutics (RLMD) position steady in Q1 2026 at 935,000 shares worth $6.51M. The position accounts for 0.86% of the portfolio, ranked #26.

Opaleye Management first reported a position in RLMD in Q3 2023 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Opaleye Management held 935,000 shares of Relmada Therapeutics worth $6.51M as of Q1 2026.
  • Opaleye Management left its Relmada Therapeutics share count unchanged in Q1 2026.
  • Relmada Therapeutics made up 0.86% of Opaleye Management's portfolio in Q1 2026, its #26 holding.
  • Opaleye Management first reported a position in Relmada Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.